BAHRAIN will soon be part of a global clinical trial to study the effect of a revolutionary drug in controlling kidney damage in patients with sickle cell anaemia.
Around 20 sickle cell disease (SCD) patients in the country will receive Crizanlizumab (Adakveo) – the first drug to become available for the disease in 20 years – as part of the trial .
&uuid=(email))